AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$BIO

Bio-Rad (BIO) Q3 2026 Earnings Call Transcript

Bio-Rad reported Q3 2026 revenue of $656M, up 0.5% YoY. Gross margin expanded to 54.5%. Clinical Diagnostics and Life Science segments showed growth, with ddPCR instrument revenue up over 20%. The company expects challenges in academic, government, and APAC markets but remains optimistic about long-term ddPCR growth.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 3:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 4:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bio-Rad (BIO) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BIONeutralHigh
01

Why it matters

Earnings provide fresh data on revenue, margins, and product momentum, informing short‑term trading decisions.

02

Market read

The earnings release offers actionable insight for traders in biotech and life‑science equities.

03

What to watch

Potential impact of NIH funding cuts and China pricing pressure could weigh on future performance.

Relevance 8/10Novelty 8/10Timing: after‑hours today

Background

Bio‑Rad presented its Q3 2026 earnings call, highlighting modest revenue growth, margin expansion, and new product launches.

Company-level read

Ticker impact

$BIONeutralMedium confidence
Context

Q3 2026 revenue $656M (+0.5% YoY), gross margin 54.5% non‑GAAP, ddPCR instrument revenue up >20%, new ChemiDoc Pro launch and guidance outlook.

Expected impact

potential modest upside as investors price in revenue beat and margin improvement

Evidence & confidence

Growth is limited but margin expansion and product launches provide a positive narrative, likely supporting a small rally.

Market effects

Sector

Life‑science and clinical diagnostics sectors may see slight uplift from Bio‑Rad's ddPCR growth.

Regional

U.S. biotech investors could adjust exposure; APAC and EMEA markets see limited direct effect.

Global

Limited to investors tracking mid‑cap biotech earnings.

Counterpoint

What could challenge this read

Despite margin expansion, flat revenue growth may signal slowing demand, suggesting caution.

Key entities

  • company
    Bio‑Rad Laboratories

    U.S. listed biotech firm reporting Q3 2026 results.

Read at source← All news

StoryBio‑Rad posts Q3 2026 results with strong profit and modest revenue outlook

Also covered by

2 outlets

Related articles

$BIOMedAI 8/10

Bio-Rad Laboratories Inc (BIO) (Q3 2026) Earnings Call Highlights: Return

Bio-Rad Laboratories reported Q3 2026 earnings, highlighting challenges in life science sales, academic funding, and China operations. Full-year revenue growth is guided between -3% and +0.5%. The company expects continued market softness but aims for positive growth in 2027. Key growth drivers include ddPCR instruments and diagnostics, with AI applications enhancing products and operations. The board is undergoing a refresh, and dialogue with Elliott Management is ongoing.

finance.yahoo.com
$BIOMedAI 8/10

What Bio-Rad Laboratories (BIO) Said on Its Q3 Earnings Call

Bio-Rad Laboratories (BIO) reported Q3 non-GAAP earnings of $2.65 per share, up from $2.26 a year earlier. The company reaffirmed its full-year revenue growth forecast of -3% to +0.5% and expects Q4 revenue to rise 5-6% sequentially. Bio-Rad aims for operating margins above 20% over time and plans to focus on positive revenue growth in 2027. Management discussed market pressures and strategic initiatives, including product launches and potential acquisitions.

finance.yahoo.com
$BIOMedAI 8/10

Bio-Rad: Q3 Earnings Snapshot

Bio-Rad Laboratories reported Q3 net income of $458.6M, up from a loss last year. EPS was $17.02, with adjusted EPS at $2.65. Revenue reached $656.4M. Shares (BIO.B) are up 22% YTD and 25% over 12 months, trading at $379.50.

finance.yahoo.com
$BIOHigh

Bio-Rad Reports Third-Quarter 2026 Financial Results

BIO-RAD LABORATORIES, INC. (BIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release Bio-Rad Reports Third -Quarter 2026 Financial Results HERCULES, Calif.—November 4, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results fo

SEC EDGAR 8-K
$BIOHighAI 8/10

Bio-Rad Reports Third-Quarter 2026 Financial Results

Bio-Rad reported Q3 2026 net sales of $656.4M, with GAAP net income of $458.6M. CEO Norman Schwartz cited growth in Clinical Diagnostics and strong demand for Droplet Digital PCR instruments. Non-GAAP operating margin was 12.8%. The company maintained its 2026 outlook, expecting non-GAAP revenue decline of 3.0% to growth of 0.5% and operating margin of 10.0% to 12.0%.

stocktitan.net